# Cluster A: 2 Viral Vector Core

> **NIH NIH P30** · UNIVERSITY OF IOWA · 2020 · $67,764

## Abstract

The Viral Vector Core (VVC) is integrated into multiple cancer projects directed at the study of the disease 
process, therapy and the pre-clinical development of vaccines. VVC staff is active participants in the 
development of gene transfer technologies in the cancer field. The interaction with multiple investigators from 
various disciplines allows for cross-fertilization of ideas, technical advancements, and innovations in vector 
designs. The VVC's overall objective is to support investigators in the use of gene transfer technologies, 
including consultation with the PI and staff, development of novel vectors, collaborative testing of vectors 
generated for function and purity, and finally routine preparation including quality control. VVC staff and 
investigators are in close contact through all phases of vector design and generation, and the VVC serves as 
both a research and development facility for gene transfer studies and a service facility for routine vector 
preparations. As a part of the service the VVC will provide purified and concentrated preparations of 
recombinant adenovirus, adeno-associated virus, vaccinia, baculovirus and retrovirus (including lentivirus). 
This facility provides access to standard cell lines, expression plasmids, and stock of recombinant reporter viral 
vectors. 
The main responsibilities of the VVC are to: prepare recombinant vectors; perform relevant quality control; 
disseminate vectors; maintain a database of vector stocks available for use; maintain a database of expression 
vectors; develop new expression vectors as needed; develop novel methods for vector production; and assist 
in the design and development of novel vectors. 
The VVC serves the needs of numerous outside cancer investigators interested in both basic and applied 
research with gene transfer vectors, and is important for several reasons. First, by keeping abreast of many 
different gene transfer vectors, approaches, and applications, the scientific expertise of the VVC staff is 
strengthened. Second, serving a broad scope of users improves and fosters inter-collegiate communication 
with focused efforts at developing improved vectors and delivery methods. Finally, a continuum of new ideas 
from both outside and within the university, and through our consultants, insures that the HCCC community 
has access to, or is aware of, the “state of the art”.

## Key facts

- **NIH application ID:** 9914240
- **Project number:** 5P30CA086862-20
- **Recipient organization:** UNIVERSITY OF IOWA
- **Principal Investigator:** PATRICK L SINN
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $67,764
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9914240

## Citation

> US National Institutes of Health, RePORTER application 9914240, Cluster A: 2 Viral Vector Core (5P30CA086862-20). Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/grant/nih/9914240. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*